Announcements Trials
Browse Landscape

Phase

Phase 2 68Phase NA 14Phase 3 14Phase 1/2 12Phase 1 10Phase 2/3 8Phase 4 6Phase EARLY_PHASE1 2

Status

Unknown 6Completed 2

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 8

Sponsor

Cancer Type

Thoracic 8

Conditions

Carcinoma, Non-Small-Cell Lung 75Lung Neoplasms 48Small Cell Lung Carcinoma 11Neoplasms 10NSCLC 8Colorectal Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Mesothelioma 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Head and Neck Neoplasms 4Adenocarcinoma of Lung 4Liver Neoplasms 3Hematologic Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Sarcoma 2Recurrence 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Laryngeal Neoplasms 2

Interventions

Pemetrexed 2Gefitinib 2spartalizumab 1aflutinib 1Tyrosine Kinase Inhibitors 1Thalidomide 1Radiosurgery 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Axitinib 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 2/3 × NSCLC × Thoracic × Clear all
NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown
113 enrolled
Thoracic

NSCLC

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown
20 enrolled
Thoracic

NSCLC

NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

The First Affiliated Hospital of Zhengzhou University

Phase 2/3 Unknown
150 enrolled
Thoracic

NSCLC

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

The First Affiliated Hospital of Henan University of Science and Technology

Phase 2/3 Unknown
90 enrolled
Thoracic

NSCLC

NCT04874844 2021-05-10

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Beijing Dongfang Biotech Co., Ltd.

Phase 2/3 Unknown
420 enrolled
Thoracic

NSCLC

NCT00259064 2016-06-02

INSTEP

AstraZeneca

Phase 2/3 Completed
216 enrolled
Thoracic

NSCLC

NCT01769066 2016-02-23

Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC

Fudan University

Phase 2/3 Completed
117 enrolled
Thoracic

NSCLC

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown
380 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡